b220-apc antibody Search Results


cd45r (b220) antibody, anti-mouse, apc-vio 770, reafinity  (Miltenyi Biotec)
95
Miltenyi Biotec cd45r (b220) antibody, anti-mouse, apc-vio 770, reafinity
Cd45r (B220) Antibody, Anti Mouse, Apc Vio 770, Reafinity, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cd45r (b220) antibody, anti-mouse, apc-vio 770, reafinity/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
cd45r (b220) antibody, anti-mouse, apc-vio 770, reafinity - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier
mouse b220/cd45r apc-conjugated antibody  (Bio-Techne corporation)
90
Bio-Techne corporation mouse b220/cd45r apc-conjugated antibody
Mouse B220/Cd45r Apc Conjugated Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/mouse b220/cd45r apc-conjugated antibody/product/Bio-Techne corporation
Average 90 stars, based on 1 article reviews
mouse b220/cd45r apc-conjugated antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
apc- b220 antibody  (Thermo Fisher)
90
Thermo Fisher apc- b220 antibody
Apc B220 Antibody, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc- b220 antibody/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
apc- b220 antibody - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
anti human cd45 apc  (Miltenyi Biotec)
97
Miltenyi Biotec anti human cd45 apc
Anti Human Cd45 Apc, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti human cd45 apc/product/Miltenyi Biotec
Average 97 stars, based on 1 article reviews
anti human cd45 apc - by Bioz Stars, 2026-03
97/100 stars
  Buy from Supplier
b cells  (Thermo Fisher)
86
Thermo Fisher b cells
B Cells, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b cells/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
b cells - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
b220-apc cy7  (Thermo Fisher)
90
Thermo Fisher b220-apc cy7
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
B220 Apc Cy7, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b220-apc cy7/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
b220-apc cy7 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
b220 apc efluor780  (Thermo Fisher)
86
Thermo Fisher b220 apc efluor780
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
B220 Apc Efluor780, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/b220 apc efluor780/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
b220 apc efluor780 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
apc-conjugated anti-b220  (Becton Dickinson)
90
Becton Dickinson apc-conjugated anti-b220
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
Apc Conjugated Anti B220, supplied by Becton Dickinson, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc-conjugated anti-b220/product/Becton Dickinson
Average 90 stars, based on 1 article reviews
apc-conjugated anti-b220 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
apc cd45  (Thermo Fisher)
86
Thermo Fisher apc cd45
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
Apc Cd45, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc cd45/product/Thermo Fisher
Average 86 stars, based on 1 article reviews
apc cd45 - by Bioz Stars, 2026-03
86/100 stars
  Buy from Supplier
biotinylated antibodies  (Miltenyi Biotec)
99
Miltenyi Biotec biotinylated antibodies
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
Biotinylated Antibodies, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/biotinylated antibodies/product/Miltenyi Biotec
Average 99 stars, based on 1 article reviews
biotinylated antibodies - by Bioz Stars, 2026-03
99/100 stars
  Buy from Supplier
pe conjugated anti-pd-1  (Thermo Fisher)
90
Thermo Fisher pe conjugated anti-pd-1
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
Pe Conjugated Anti Pd 1, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pe conjugated anti-pd-1/product/Thermo Fisher
Average 90 stars, based on 1 article reviews
pe conjugated anti-pd-1 - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier
apc vio770 anti cd45ro  (Miltenyi Biotec)
95
Miltenyi Biotec apc vio770 anti cd45ro
(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or <t>B220</t> + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).
Apc Vio770 Anti Cd45ro, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/apc vio770 anti cd45ro/product/Miltenyi Biotec
Average 95 stars, based on 1 article reviews
apc vio770 anti cd45ro - by Bioz Stars, 2026-03
95/100 stars
  Buy from Supplier

Image Search Results


(A) BrdU staining showing no significant proliferative changes in CD3 + T cells or B220 + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).

Journal: PLoS ONE

Article Title: Effects of subconjunctival administration of anti-high mobility group box 1 on dry eye in a mouse model of Sjӧgren’s syndrome

doi: 10.1371/journal.pone.0183678

Figure Lengend Snippet: (A) BrdU staining showing no significant proliferative changes in CD3 + T cells or B220 + B cells. (B) Percentage of Th17 (CD3 + CD4 + IL-17 hi ) cells and Tc17 (CD3 + CD8 + IL-17 hi ) cells were not altered after treatment. (C) IFNγ-secreting T cells (CD3 + CD4 + IFNγ hi or CD3 + CD8 + IFNγ hi ) were not affected by treatment. Data are presented as mean ± standard error. (Th17, T helper cells secreting IL-17; Tc17, cytotoxic T cells secreting IL-17).

Article Snippet: Color conjugation combinations and gating strategies were as follows: (1) IFNγ, and IL-17A secreting cells; CD3-PerCP cy5.5 (eBioscience, 145-2C11), CD4-APC (eBioscience, GK1.5), CD8-PE cy7 (eBioscience, 53–6.7), B220-APC cy7 (eBioscience, RA3-6B2), IL-17A-PE (BD Pharmingen ™ , TC11-18H10), IFNγ-FITC (eBioscience, XMG1.2); (2) Plasma cells; CD3-PerCP cy5.5 (eBioscience, 145-2C11), B220-APC cy7 (eBioscience, RA3-6B2), CD138-APC (BD Pharmingen ™ , 281–2); (3) IL-10 secreting B cells; CD3-PE (eBioscience, 145-2C11), CD19-PerCP cy5.5 (eBioscience, eBio 1D3), B220-APC cy7 (eBioscience, RA3-6B2), IL-10-FITC (eBioscience, JES5-16E3); (4) ILC3s; CD3-PerCP cy5.5 (eBioscience, 145-2C11), B220-FITC (eBioscience, RA3-6B2), NKp46-APC (eBioscience, 29A1.4), CD45-APC cy7 (eBioscience, 30-F11), IL-22-PE (eBioscience, 1H8PWSR).

Techniques: BrdU Staining

(A) No significant change in percentage of plasma cells (CD3 - B220 + CD138 + cells). (B) No change in IL-10-secreting B regulatory cells (CD3 - CD19 + B220 + IL-10 hi ). (C) No change in the level of anti-SSA (RO 60) antibodies after treatment. (D) No significant changes in inflammatory foci scores (> 50 lymphocytes/focus) among all groups. Data are presented as mean ± standard error.

Journal: PLoS ONE

Article Title: Effects of subconjunctival administration of anti-high mobility group box 1 on dry eye in a mouse model of Sjӧgren’s syndrome

doi: 10.1371/journal.pone.0183678

Figure Lengend Snippet: (A) No significant change in percentage of plasma cells (CD3 - B220 + CD138 + cells). (B) No change in IL-10-secreting B regulatory cells (CD3 - CD19 + B220 + IL-10 hi ). (C) No change in the level of anti-SSA (RO 60) antibodies after treatment. (D) No significant changes in inflammatory foci scores (> 50 lymphocytes/focus) among all groups. Data are presented as mean ± standard error.

Article Snippet: Color conjugation combinations and gating strategies were as follows: (1) IFNγ, and IL-17A secreting cells; CD3-PerCP cy5.5 (eBioscience, 145-2C11), CD4-APC (eBioscience, GK1.5), CD8-PE cy7 (eBioscience, 53–6.7), B220-APC cy7 (eBioscience, RA3-6B2), IL-17A-PE (BD Pharmingen ™ , TC11-18H10), IFNγ-FITC (eBioscience, XMG1.2); (2) Plasma cells; CD3-PerCP cy5.5 (eBioscience, 145-2C11), B220-APC cy7 (eBioscience, RA3-6B2), CD138-APC (BD Pharmingen ™ , 281–2); (3) IL-10 secreting B cells; CD3-PE (eBioscience, 145-2C11), CD19-PerCP cy5.5 (eBioscience, eBio 1D3), B220-APC cy7 (eBioscience, RA3-6B2), IL-10-FITC (eBioscience, JES5-16E3); (4) ILC3s; CD3-PerCP cy5.5 (eBioscience, 145-2C11), B220-FITC (eBioscience, RA3-6B2), NKp46-APC (eBioscience, 29A1.4), CD45-APC cy7 (eBioscience, 30-F11), IL-22-PE (eBioscience, 1H8PWSR).

Techniques: Hi-C

(A) Fold changes in ILC3 percentage (CD3 - B220 - CD45 + IL-22 hi cells; NCR + or NCR - ILC3) showing a significant increase following 2 μg anti-HMGB1 treatment compared with control (Kruskal-Wallis test, PBS vs. 2μg anti-HMGB1, *p = 0.025). Fold increase in NCR - ILC3 percentage (CD3 - B220 - CD45 + NKp46 - IL-22 hi cells)(Kruskal-Wallis test, PBS vs. 2 μg anti-HMGB1, **p = 0.0142). (B) Increased IL-22 levels after 2 μg anti-HMGB1 treatment (Kruskal-Wallis test, PBS vs. 2 μg anti-HMGB1, *p = 0.025). (C) No change in percentage of CD3 + IL-22 hi cells (Th22 cells or γδ T cells) in draining lymph nodes. Data are presented as mean ± standard error. (D) Representative images of NCR - ILC3s (CD3 - B220 - CD45 + NKp46 - IL-22 hi cells) in PBS- and 2 μg anti-HMGB1-treated groups. NCR, natural cytotoxicity receptor.

Journal: PLoS ONE

Article Title: Effects of subconjunctival administration of anti-high mobility group box 1 on dry eye in a mouse model of Sjӧgren’s syndrome

doi: 10.1371/journal.pone.0183678

Figure Lengend Snippet: (A) Fold changes in ILC3 percentage (CD3 - B220 - CD45 + IL-22 hi cells; NCR + or NCR - ILC3) showing a significant increase following 2 μg anti-HMGB1 treatment compared with control (Kruskal-Wallis test, PBS vs. 2μg anti-HMGB1, *p = 0.025). Fold increase in NCR - ILC3 percentage (CD3 - B220 - CD45 + NKp46 - IL-22 hi cells)(Kruskal-Wallis test, PBS vs. 2 μg anti-HMGB1, **p = 0.0142). (B) Increased IL-22 levels after 2 μg anti-HMGB1 treatment (Kruskal-Wallis test, PBS vs. 2 μg anti-HMGB1, *p = 0.025). (C) No change in percentage of CD3 + IL-22 hi cells (Th22 cells or γδ T cells) in draining lymph nodes. Data are presented as mean ± standard error. (D) Representative images of NCR - ILC3s (CD3 - B220 - CD45 + NKp46 - IL-22 hi cells) in PBS- and 2 μg anti-HMGB1-treated groups. NCR, natural cytotoxicity receptor.

Article Snippet: Color conjugation combinations and gating strategies were as follows: (1) IFNγ, and IL-17A secreting cells; CD3-PerCP cy5.5 (eBioscience, 145-2C11), CD4-APC (eBioscience, GK1.5), CD8-PE cy7 (eBioscience, 53–6.7), B220-APC cy7 (eBioscience, RA3-6B2), IL-17A-PE (BD Pharmingen ™ , TC11-18H10), IFNγ-FITC (eBioscience, XMG1.2); (2) Plasma cells; CD3-PerCP cy5.5 (eBioscience, 145-2C11), B220-APC cy7 (eBioscience, RA3-6B2), CD138-APC (BD Pharmingen ™ , 281–2); (3) IL-10 secreting B cells; CD3-PE (eBioscience, 145-2C11), CD19-PerCP cy5.5 (eBioscience, eBio 1D3), B220-APC cy7 (eBioscience, RA3-6B2), IL-10-FITC (eBioscience, JES5-16E3); (4) ILC3s; CD3-PerCP cy5.5 (eBioscience, 145-2C11), B220-FITC (eBioscience, RA3-6B2), NKp46-APC (eBioscience, 29A1.4), CD45-APC cy7 (eBioscience, 30-F11), IL-22-PE (eBioscience, 1H8PWSR).

Techniques: